活動実績活動実績

1.論文発表(英文発表)

2019

1:Katsutoshi Sugimoto,Kazuhiro Kakimi,Hirohito Takeuchi,Nao Fujieda,Kazuhiro Saito,Eiichi Sato,Kentaro Sakamaki, Fuminori Moriyasu and Takao Itoi.Irreversible Electroporation versus Radiofrequency Ablation:Comparison of Systemic Immune Responses in Patients with Hepatocellular Carcinoma.2019 March 3;30:845-853

 

2018

1: Hoshikawa M, Aoki T, Matsushita H, Karasaki T, Hosoi A, Odaira K, Fujieda N, Kobayashi Y, Kambara K, Ohara O, Arita J, Hasegawa K, Kakimi K, Kokudo N.  NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer. Biochem Biophys Res Commun. 2018 Jan 8;495(2):2058-2065.

2:Hosoi A, Takeda K, Nagaoka K, Iino T, Matsushita H, Ueha S, Aoki S, Matsushima K, Kubo M, Morikawa T, Kitaura K, Suzuki R, Kakimi K. Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy. SCIENITIFIC REPORTS. 2018 Jan 18;8(1):1058.

3: Yamamoto M, Nomura S, Hosoi A, Nagaoka K, Iino T, Yasuda T, Saito T, Matsushita H, Uchida E, Seto Y, Goldenring JR, Kakimi K, Tatematsu M, Tsukamoto. Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth. Cancer Sci. 2018 May;109(5):1480-1492.

4: Imai Y, Hasegawa K, Matsushita H, Fujieda N, Sato S, Miyagi E, Kakimi K, Fujiwara K. Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma. Oncol Lett. 2018, May;15(5):6457-6468.

5: Karasaki T, Qiang G, Anraku M, Sun Y, Shinozaki-Ushiku A, Sato E, Kashiwabara K, Nagayama K, Nitadori JI, Sato M, Murakawa T, Kakimi K, Fukayama M, Nakajima J. High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma. J Thorac Dis. 2018 Aug;10(8):4741-4750.

6: Kawashima M, Sato M, Murakawa T, Anraku M, Konoeda C, Hosoi A, Kakimi K, Nakajima J. Role of Toll-like Receptor 4 Expressed by Fibroblasts in Allograft Fibrosis in Mouse Orthotopic Tracheal Transplantation. Transplant Proc. 2018 Dec;50(10):3863-3872.

2017

1: Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Takazawa M, Ohara O, Nakajima J, Kakimi K.
Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
Cancer Sci. 2017 Feb;108(2):170-177.

2: Aoki T, Matsushita H, Hoshikawa M, Hasegawa K, Kokudo N, Kakimi K.
Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer.
Cytotherapy. 2017 Feb 7.

3: Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nakajima J.
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
J Thorac Oncol. 2017 Jan 11

4: Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Takazawa M, Ohara O, Nakajima J, Kakimi K.
Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
Cancer Sci. 2017 Feb;108(2):170-177.

5: Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K.
The frequency of neoantigens per somatic mutation rater than overall mutational load or number of presicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.
Oncoimmunology. 2017 Jul 14;6(8):e1338996.

6: Nagaoka K, Hosoi A, Iino T, Morishita Y, Matsushita H, Kakimi K.
Dendritic cell vaccine induces antigen-specific CD8+Tcells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade.
Oncoimmunology. 2017 Nov 20;7(3):e1395124.

7: Ando K, Fujita H, Hosoi A, Ma L, Wakatsuki M, Seino KI, Kakimi K, Imai T. Shimokawa T, Nakano T.                                                                      Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation.                                                        J Radiat Res. 2017 Jul 1;58(4):446-455.

 

2016

1: Karasaki T, Nagayama K, Kawashima M, Hiyama N, Murayama T, Kuwano H, Nitadori J, Anraku M, Sato M, Miyai M, Hosoi A, Matsushita H, Kikugawa S, Matoba R, Ohara O, Kakimi K, Nakajima J.
Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
J Thorac Oncol. 2016 Mar;11(3):324-33.

2: Makise N, Morikawa T, Nakagawa T, Ichimura T, Kawai T, Matsushita H, Kakimi K, Kume H, Homma Y, Fukayama M.
MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma.
Hum Pathol. 2016 Apr;50:62-9.

3: Matsushita H, Sato Y, Karasaki T, Nakagawa T, Kume H, Ogawa S, Homma Y, Kakimi K.
Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.
Cancer Immunol Res. 2016 May;4(5):463-71.

4: Odaira K, Kimura SN, Fujieda N, Kobayashi Y, Kambara K, Takahashi T, Izumi T, Matsushita H, Kakimi K.
CD27(-)CD45(+) γδ T cells can be divided into two populations, CD27(-)CD45(int) and CD27(-)CD45(hi) with little proliferation potential.
Biochem Biophys Res Commun. 2016 Sep 23;478(3):1298-303.

2015

1: Sato Y, Shimizu K, Shinga J, Hidaka M, Kawano F, Kakimi K, Yamasaki S, Asakura M, Fujii SI.
Characterization of the myeloid-derived suppressor cell subset
regulated by NK cells in malignant lymphoma.
Oncoimmunology. 2015 Jan 22;4(3):e995541. eCollection 2015 Mar. PubMed PMID: 25949922; PubMed Central PMCID: PMC4404816.

2: Ueha S, Yokochi S, Ishiwata Y, Ogiwara H, Chand K, Nakajima T, Hachiga K, Shichino S, Terashima Y, Toda E, Shand FH, Kakimi K, Ito S, Matsushima K.
Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
Cancer Immunol Res. 2015 Jun;3(6):631-40. doi: 10.1158/2326-6066.CIR-14-0190. Epub 2015 Feb 20. PubMed PMID: 25711759.

3: Hirano K, Hosoi A, Matsushita H, Iino T, Ueha S, Matsushima K, Seto Y, Kakimi K.
The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy.
Oncoimmunology. 2015 Apr 1;4(8):e1019195.

4: Futami J, Nonomura H, Kido M, Niidoi N, Fujieda N, Hosoi A, Fujita K, Mandai K, Atago Y, Kinoshita R, Honjo T, Matsushita H, Uenaka A, Nakayama E, Kakimi K.
Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically S-Cationized Full-Length and Water-Soluble Denatured Proteins.
Bioconjug Chem. 2015 Oct 21;26(10):2076-84.

5: Miyai M, Eikawa S, Hosoi A, Iino T, Matsushita H, Isobe M, Uenaka A, Udono H, Nakajima J, Nakayama E, Kakimi K.
Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.
PLoS One. 2015 Aug 20;10(8)

6: Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E.
Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.
Clin Cancer Res. 2015 Oct 1;21(19):4327-36.

7: Futami J, Nonomura H, Kido M, Niidoi N, Fujieda N, Hosoi A, Fujita K, Mandai K, Atago Y, Kinoshita R, Honjo T, Matsushita H, Uenaka A, Nakayama E, Kakimi K.
Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically S-Cationized Full-Length and Water-Soluble Denatured Proteins.
Bioconjug Chem. 2015 Oct 21;26(10):2076-84. doi: 10.1021/acs.bioconjchem.5b00328. PMID: 26355635

8: 2015 Guidance on cancer immunotherapy development in early-phase clinical studies.
Guidance Development Review Committee.; Working Group for Clinical Studies of Cancer Immunotherapy.; Working Group for Effector Cell Therapy.; Working Group for CMC/Non-clinical Studies.; Working Group for Cancer Vaccines and Adjuvants.; Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy.; Biostatistics Subcommittee..
Cancer Sci. 2015 Dec;106(12):1761-71.

2014

1: Kawai T, Enomoto Y, Morikawa T, Matsushita H, Kume H, Fukayama M, Yamaguchi H, Kakimi K, Homma Y.
High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy.
Mol Clin Oncol. 2014 Jan;2(1):38-42.

2: Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E.
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
J Immunother. 2014 Feb-Mar;37(2):84-92.

3: Ichimura T, Morikawa T, Kawai T, Nakagawa T, Matsushita H, Kakimi K, Kume H, Ishikawa S, Homma Y, Fukayama M.
Prognostic Significance of CD204-Positive Macrophages in Upper Urinary Tract Cancer.
Ann Surg Oncol. 2014 Feb 4. [Epub ahead of print]

4: Mizote Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E.
Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.
Vaccine. 2014 Feb 12;32(8):957-64.

5: Kazuhiro K, Hirokazu M, Tomohiro M, Jun N.
γδ T cell therapy for the treatment of non-small cell lung cancer
Transl Lung Cancer Res 2014;3(1):23-33

6: Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K.
Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.
Cancer Med. 2014 Apr;3(2):362-75.

7: Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, Kakimi K.
Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Int J Cancer. 2014 Apr 15;134(8):1810-22.

8: Yamada D, Matsushita H, Azuma T, Nakagawa T, Nagata M, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Homma Y, Kakimi K.
Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy.
Mol Clin Oncol. 2014 Nov;2(6):1023-1027.

9: Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, Maekawa R, Matsushima K, Ohara O, Kakimi K.
Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN-γ-dependent cell cycle arrest.
Cancer Immunol Res. 2014 Aug 15. [Epub ahead of print]

10: Matsushita H, Enomoto H, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y and Kakimi K.
A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma.
Journal for Immunotherapy of Cancer 2014, 2:30

11: Kakimi K, Matsushita H, Hosoi A, Miyai M, Ohara O. CTLs regulate tumor growth
via cytostatic effects rather than cytotoxicity: a few T cells can influence the
growth of many times more tumor cells. Oncoimmunology. 2014 Dec 3;4(3):e970464.
eCollection 2015 Mar. PubMed PMID: 25949889; PubMed Central PMCID: PMC4404888.

12: Futami J, Fujiyama H, Kinoshita R, Nonomura H, Honjo T, Tada H, Matsushita H,
Abe Y, Kakimi K. Denatured mammalian protein mixtures exhibit unusually high
solubility in nucleic acid-free pure water. PLoS One. 2014 Nov 18;9(11):e113295.
doi: 10.1371/journal.pone.0113295. eCollection 2014. PubMed PMID: 25405999;
PubMed Central PMCID: PMC4236158.

13: Kobayashi T, Kakimi K, Nakayama E, Jimbow K. Antitumor immunity by magnetic
nanoparticle-mediated hyperthermia. Nanomedicine (Lond). 2014 Aug;9(11):1715-26.
doi: 10.2217/nnm.14.106. Review. PubMed PMID: 25321171.

2013

1: Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV.
CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion.
PLoS Pathog. 2013;9(7):e1003490. doi: 10.1371/journal.ppat.1003490.

2: Shimizu K, Mizuno T, Shinga J, Asakura M, Kakimi K, Ishii Y, Masuda K, Maeda T, Sugahara H, Sato Y, Matsushita H, Nishida K, Hanada K, Dorrie J, Schaft N, Bickham K, Koike H, Ando T, Nagai R, Fujii S.
Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.
Cancer Res. 2013 Jan 1;73(1):62-73.

3: Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E.
Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
Int J Cancer. 2013 Jan 15;132(2):345-54.

4: Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K.
Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Cytotherapy. 2013 Apr;15(4):481-91.

5: Konoeda C, Koinuma D, Morishita Y, Sano A, Nagayama K, Motomura N, Kakimi K, Miyazono K, Nakajima J, Nicolls MR, Murakawa T.
Epithelial to mesenchymal transition in murine tracheal allotransplantation: an immunohistochemical observation.
Transplant Proc. 2013 Jun;45(5):1797-801.

6: Dewi N, Yanagie H, Zhu H, Demachi K, Shinohara A, Yokoyama K, Sekino M, Sakurai Y, Morishita Y, Iyomoto N, Nagasaki T, Horiguchi Y, Nagasaki Y, Nakajima J, Ono M, Kakimi K, Takahashi H.
Tumor growth suppression by gadolinium-neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent.
Biomed Pharmacother. 2013 Jul;67(6):451-7.

2012

1: Abe J, Ueha S, Yoneyama H, Shono Y, Kurachi M, Goto A, Fukayama M, Tomura M, Kakimi K, Matsushima K. B cells regulate antibody responses through the medullary remodeling of inflamed lymph nodes. Int Immunol. 2012 Jan;24(1):17-27.

2: Kato Y, Kajiwara C, Ishige I, Mizukami S, Yamazaki C, Eikawa S, Kakimi K, Udono H. HSP70 and HSP90 Differentially Regulate Translocation of Extracellular Antigen to the Cytosol for Cross-Presentation. Autoimmune Dis. 2012;2012:745962.

3: Noji S, Hosoi A, Takeda K, Matsushita H, Morishita Y, Seto Y, Kakimi K. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy. J Immunother. 2012 Jul;35(6):460-72.

2011

1: Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. J Immunother. 2011 Mar;34(2):202-11.

2: Yoshida Y, Nakajima J, Wada H, Kakimi K. γδ T-cell immunotherapy for lung cancer. Surg Today. 2011 May;41(5):606-11.

3: Matsushita H, Kakimi K, Tomita Y, Tatsugami K, Naito S, Suekane S, Noguchi M, Moriya F, Matsuoka K, Itoh K, Kobayashi H, Eto M, Takahashi W, Kawano Y, Wada Y. Exploring immune therapy for renal cancer. Int J Urol. 2011 Jun;18(6):412-21.

4: Kurachi M, Kurachi J, Suenaga F, Tsukui T, Abe J, Ueha S, Tomura M, Sugihara K, Takamura S, Kakimi K, Matsushima K. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med. 2011 Aug 1;208(8):1605-20.

5: Toda M, Wang L, Ogura S, Torii M, Kurachi M, Kakimi K, Nishikawa H, Matsushima K, Shiku H, Kuribayashi K, Kato T. UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. Int J Cancer. 2011 Sep 1;129(5):1126-36.

6: Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, Kakimi K. Expansion of human peripheral blood γδ T cells using zoledronate. J Vis Exp. 2011 Sep 9;(55). pii: 3182. doi: 10.3791/3182.

7: Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY -ESO-1 antigen. Int J Cancer. 2011 Dec 15;129(12):2836-46.

2010

1: Ikeuchi N, Futami J, Hosoi A, Noji S, Kurachi M, Ueha S, Fujii S, Yamada H, Matsushima K, Moriyasu F, Kakimi K. Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide. Biochem Biophys Res Commun. 2010 Feb 5;392(2):217-22.

2: Kimura K, Nagaki M, Matsuura T, Moriwaki H, Kakimi K. Pathological role of CD44 on NKT cells in carbon tetrachloride-mediated liver injury. Hepatol Res. 2009 Jan;39(1):93-105.

3: Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, Yoshida Y, Kakimi K. Impact of culture medium on the expansion of T cells for immunotherapy. Cytotherapy. 2009;11(7):936-46.

4: Narui K, Noguchi N, Saito A, Kakimi K, Motomura N, Kubo K, Takamoto S, Sasatsu M. Anti-infectious activity of tryptophan metabolites in the L-tryptophan-L-kynurenine pathway. Biol Pharm Bull. 2009 Jan;32(1):41-4.

5: Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer. 2009 Jul;65(1):1-8.

2009

1: Kimura K, Nagaki M, Saio M, Moriwaki H, Kakimi K. Role of CD44 in CTL-induced acute liver injury in hepatitis B virus transgenic mice. J Gastroenterol. 2009;44(3):218-27.

2: Kimura K, Nagaki M, Matsuura T, Moriwaki H, Kakimi K. Pathological role of CD44 on NKT cells in carbon tetrachloride-mediated liver injury. Hepatol Res. 2009 Jan;39(1):93-105.

3: Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, Yoshida Y, Kakimi K. Impact of culture medium on the expansion of T cells for immunotherapy. Cytotherapy. 2009;11(7):936-46.

4: Narui K, Noguchi N, Saito A, Kakimi K, Motomura N, Kubo K, Takamoto S, Sasatsu M. Anti-infectious activity of tryptophan metabolites in the L-tryptophan-L-kynurenine pathway. Biol Pharm Bull. 2009 Jan;32(1):41-4.

5: Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer. 2009 Jul;65(1):1-8.

2008

1: Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, Shiraishi K, Nakagawa K, Kakimi K. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 2008;10(8):842-56.

2: Hosoi A, Takeda Y, Furuichi Y, Kurachi M, Kimura K, Maekawa R, Takatsu K, Kakimi K. Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization. Cancer Res. 2008 May 15;68(10):3941-9.

3: Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, Kuwata K, Moriwaki H. Critical role of CD44 in hepatotoxin-mediated liver injury. J Hepatol. 2008 Jun;48(6):952-61.

4: Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, Shono Y, Kitabatake M, Kakimi K, Mukaida N, Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008 Jun 15;111(12):5457-66.

5: Hosoi A, Takeda Y, Sakuta K, Ueha S, Kurachi M, Kimura K, Maekawa R, Kakimi K. Dendritic cell vaccine with mRNA targeted to the proteasome by polyubiquitination. Biochem Biophys Res Commun. 2008 Jun 27;371(2):242-6.

6: Saito A, Motomura N, Kakimi K, Narui K, Noguchi N, Sasatsu M, Kubo K, Koezuka Y, Takai D, Ueha S, Takamoto S. Vascular allografts are resistant to methicillin-resistant Staphylococcus aureus through indoleamine 2,3-dioxygenase in a murine model. J Thorac Cardiovasc Surg. 2008 Jul;136(1):159-67.

2007

1: Kurachi M, Kakimi K, Ueha S, Matsushima K. Maintenance of memory CD8+ T cell diversity and proliferative potential by a primary response upon re-challenge. Int Immunol. 2007 Jan;19(1):105-15.

2: Uno K, Hirosaki M, Kakimi K, Tominaga M, Suginoshita Y, Hasegawa G, Fukui M, Nakamura N, Shirakawa T, Kishida T. Impaired IFN-alpha production and the risk of cancer development. J Interferon Cytokine Res. 2007 Dec;27(12):1013-7.

2006

1: Saito A, Motomura N, Kakimi K, Ono M, Takai D, Sumida S, Takamoto S. Cryopreservation does not alter the allogenicity and development of vasculopathy in post-transplant rat aortas. Cryobiology. 2006 Apr;52(2):251-60.

2: Uno K, Suginoshita Y, Kakimi K, Moriyasu Y, Nakano K, Nakamura N, Fujita T, Horino Y, Sato T, Kishida T. Clinical utility of 2′,5′-oligoadenylate synthetase activity measurement: using whole blood as a highly sensitive method to detect the effects of IFN. J Virol Methods. 2006 Sep;136(1-2):185-92.

3: Matsuda Y, Toda M, Kato T, Kuribayashi K, Kakimi K. Fulminant liver failure triggered by therapeutic antibody treatment in a mouse model. Int J Oncol. 2006 Nov;29(5):1119-25.

4: Sasawatari S, Tadaki T, Isogai M, Takahara M, Nieda M, Kakimi K. Efficient priming and expansion of antigen-specific CD8+ T cells by a novel cell-based artificial APC. Immunol Cell Biol. 2006 Dec;84(6):512-21.

2005

1: Isogawa M, Kakimi K, Kamamoto H, Protzer U, Chisari FV. Differential dynamics of the peripheral and intrahepatic cytotoxic T lymphocyte response to hepatitis B surface antigen. Virology. 2005 Mar 15;333(2):293-300.

2: Furuichi Y, Tokuyama H, Ueha S, Kurachi M, Moriyasu F, Kakimi K. Depletion of CD25+CD4+T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization. World J Gastroenterol. 2005 Jun 28;11(24):3772-7.

3: Tokuyama H, Ueha S, Kurachi M, Matsushima K, Moriyasu F, Blumberg RS, Kakimi K. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol. 2005 Aug;17(8):1023-34.

4: Takai S, Kimura K, Nagaki M, Satake S, Kakimi K, Moriwaki H. Blockade of neutrophil elastase attenuates severe liver injury in hepatitis B transgenic mice. J Virol. 2005 Dec;79(24):15142-50.

5: Uno K, Suginoshita Y, Kakimi K, Moriyasu F, Hirosaki M, Shirakawa T, Kishida T. Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma. World J Gastroenterol. 2005 Dec 14;11(46):7330-4.